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Background
Rheumatoid arthritis (RA) commonly involves the car-
diovascular system, and is associated with significant
morbidity and mortality. Mechanisms of cardiovascu-
lar disease (CVD) involvement are not fully under-
stood, but cardiovascular inflammation is thought to
drive many of the CVD manifestations, including myo-
cardial ischaemia. The clinical utility of CMR first-
pass perfusion for assessment of myocardial ischaemia
is well-established. The aim of this study was to assess
whether RA patients without known epicardial coron-
ary artery disease have evidence of myocardial
hypoperfusion.
Methods
55 RA patients (39 female, mean age 54 ± 11 years)
with 55 matched controls (39 female, mean age 53 ±
10 years) were enrolled into the study. All patients
with known cardiovascular disease were excluded.
Study participants underwent CMR at 1.5T and the
assessments included cine, tagging, T1 mapping, T2-
weighted, perfusion, late gadolinium (0.15mmol/kg
gadoteric acid - Dotarem®) imaging and ECV quantifi-
cation. Comorbid status, disease activity index
(DAS28-CRP) and duration of disease were recorded
for each subject.
Results
RA patients and controls were well matched for age,
sex and comorbidities (Table 1). There was no signifi-
cant difference in LV size, mass and ejection fraction
between RA patients and controls (Table 2). Peak sys-
tolic circumferential strain and peak diastolic strain
rate were impaired in patients. Myocardial perfusion
reserve index was 1.5 ± 0.3 and 1.9 ± 0.4 (p<0.001) in
RA and controls, respectively. Non-segmental (circum-
ferential) subendocardial perfusion defects were seen
in 47% and none (p<0.001) of RA patients and controls
studied. Impaired MPRI correlated with peak systolic
strain (R -0.71, p<0.001) and peak diastolic strain rate
(R 0.63, p<0.001) in RA (Figure 1). Further, abnormal
MPRI was associated with DAS28-CRP (R -0.38,
p=0.005) and volume fraction of T2 SI ratio (R -0.29,
p=0.036) in RA.
Conclusions
Myocardial perfusion is impaired in about half of
asymptomatic RA patients with apparently normal
hearts likely due to microvascular dysfunction. Abnor-
mal perfusion reserve correlates with myocardial strain
and RA disease activity.
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Table 1 Baseline characteristics of RA patients and controls
Controls N=55 RA N=55 P value
Female sex, n (%) 39 (71) 39 (71) 1.00
Age, years 53 ± 10 54 ± 11 0.70
Hypertension, n(%) 4 (7) 9 (16) 0.24
Diabetes, n(%) 0 3 (5) -
Hyperlipidaemia, n(%) 11 (20) 9 (16) 0.75
BMI, kg/m2 24 ± 4 26 ± 4 0.06
Methotrexate, n(%) N/A 50 (91) -
Chloroquine, n(%) N/A 30 (55) -
Leflunomide, n(%) N/A 10 (18) -
Sulfasalazine, n(%) N/A 8 (15) -
Rituximab, n(%) N/A 3 (5) -
Prednisolone, n(%) N/A 5 (9) -
DAS28-CRP N/A 3.4 ± 1.4 -
ESR, mm/hr (median, IQR) N/A 13 (8-17) -
CRP, mg/L (median, IQR) 1 (1-2) 10 (5-16) <0.001
Duration of RA, years (median, IQR) N/A 9 (5-13) -
Duration of DMARDs, years (median, IQR) N/A 6 (3-8) -
RF positive, n (%) N/A 45 (82) -
ACCP positive, n (%) N/A 38 (69) -
Continuous data are mean ± SD unless otherwise indicated.
Categorical data are frequency (percent) unless otherwise indicated.
ACCP, anti-cyclic citrullinated peptide antibodies; BMI, body mass index; CRP, C-reactive protein; DAS28-CRP, rheumatoid arthritis disease activity index
incorporating 28 tender and swollen joint count and serum CRP; DMARD, disease modifying anti-rheumatic drug(s); ESR, erythrocyte sedimentation rate; IQR,
interquartile range; RA, rheumatoid arthritis; RF, rheumatoid factor
Table 2 Myocardial structure, function and perfusion in RA patients and controls
Controls N=55 RA N=55 P value
LVEDV indexed to BSA, ml/m2 78 ± 15 79 ± 15 0.92
LVESV indexed to BSA, ml/m2 22 ± 14 22 ± 8 0.96
LVEF, % 74 ± 4 72 ± 7 0.45
LV Mass indexed to BSA, g/m2 54 ± 11 55 ± 11 0.64
LA size, mm 27 ± 5 32 ± 6 <0.001
Mid SA circumferential strain -18.7 ± 1.2 -17.0 ± 1.1 <0.001
Peak diastolic circumferential strain rate (s-1) 115 ± 21 82 ± 19 <0.001
Presence of LGE (%) 0 27 (49) -
Volume fraction of LGE>2SD (%) 0 3.8 ± 0.3 -
Global myocardial T2 SI Ratio 1.5 ± 0.1 1.7 ± 0.3 <0.001
Volume fraction of oedema by T2 (%) 0 20 (8-33) -
Average myocardial T1, ms 958 ± 26 971 ± 23 <0.001
Volume fraction of T1>990ms (%) 1 (1-6) 32 (18-49) <0.001
ECV (%) 27.4 ± 2.9 30.1 ± 3.2 <0.001
Rest RPP 8, 982 ± 1, 716 8, 807 ± 1, 347 0.13
Stress RPP 11, 360 ± 1, 835 12, 530 ± 2, 547 <0.001
MPRI 1.9 ± 0.4 1.5 ± 0.3 <0.001
Proportion of non-segmental perfusion defects (%) 0 27 (49) -
Continuous data are mean ± SD unless otherwise indicated.
ECV, extracellular volume; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left
ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MPRI, myocardial perfusion reserve index; RA, rheumatoid arthritis; RPP, rate pressure
product; SA, short axis; SI, signal intensity
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